It is imperative to highlight the importance of identifying carriers of PV in any of the MMR genes or other clinically actionable high-risk genes, who would benefit from either surveillance, targeted therapy, or risk-reducing surgery. This evidence concerns the gene MRC1 and acquired polycythemia vera.